Factors Influencing Cardiopulmonary Exercise Testing in Obstructive Sleep Apnea Syndrome Patients

Cristiane Yamabayashi, Hideaki Nakayama, Naho Matsuyama, Takeo Watanabe, Kunihiko Sakai, Tetsuro Ohdaira, Toshinori Takada, Kohei Akazawa, Kuriko Kobayashi, and Fumitake Gejiyo

Division of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Department of Respiratory Medicine, Nishi-Niigata Chuo National Hospital, Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan

Received September 2, 2006; accepted December 11, 2006

Summary. The exercise capacity of obstructive sleep apnea syndrome (OSAS) patients has been demonstrated to be impaired, but the factors responsible are still unclear. In addition, ventilatory efficiency during exercise has never been studied in OSAS. Hypertension (HT), commonly found in OSAS patients, could be a contributing factor to exercise capacity. The aim of the study is: 1) to determine possible factors that could influence the exercise capacity of OSAS patients, and 2) to compare the exercise capacity and ventilatory efficiency of patients with and without HT. Twenty-two male OSAS patients were submitted to cardiopulmonary exercise testing. Multiple linear regression analyses were used to find possible factors that could influence the exercise capacity and ventilatory efficiency of OSAS patients. Patients were divided into two groups according to the presence of HT, and cardiopulmonary exercise testing (CPET) results were compared between them. No factors emerged as predictors of oxygen consumption at peak exercise (VO2peak). The slope of increase of ventilation relative to carbon dioxide production (VE/VC02-slope) was associated with body mass index (BMI) negatively and with apnea-hypopnea index (AHI) positively (p = 0.019 and p = 0.047, respectively). There were no differences in either VO2peak or anaerobic threshold (AT) between OSAS with and without HT, but the VE/VC02-slope was higher in the HT group (p = 0.008). Our results suggest that the severity of sleep apnea can influence the ventilatory efficiency of OSAS patients along with BMI and HT.

Key words—body mass index, exercise test, hypertension, obstructive sleep apnea, severity of illness index.

INTRODUCTION

Obstructive sleep apnea syndrome (OSAS) patients always complain of diurnal sleepiness and fatigue. Cardiopulmonary exercise testing (CPET) is a valuable tool in the evaluation of cardiac, pulmonary, and muscle function. In OSAS patients, it can help to quantify the level of the patient’s exercise limitations and to assess improvement after treatment. There are a limited number of studies addressing exercise capacity in OSAS patients. Some of these have shown diminished exercise ability in OSAS, with lower maximum oxygen consumption (VO2max) and anaerobic threshold (AT) during exercise compared with normotensive patients. Factors responsible for this decrease in exercise capacity are still unclear because each may reciprocally influence other factors; thus, the most influential factor on exercise capacity can not be easily determined.

Hypertension (HT), commonly found in OSAS, could be one confounding factor in some of the studies addressing exercise capacity in OSAS. As improvement of exercise capacity after continuous positive airway pressure (CPAP) treatment has also been reported, the severity of the disease could probably be reflected in the exercise limitations of these patients. The only report showing a correlation between exercise capacity and HT.

Correspondence: Hideaki Nakayama M.D., PhD., Division of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Niigata University, 1–757 Asahimachi-dori, Niigata 951–8510, Japan.

Abbreviations—AHI, apnea-hypopnea index; AT, anaerobic threshold; BMI, body mass index; HT, hypertension; OSAS, obstructive sleep apnea syndrome; SPB and DBP, systolic and diastolic blood pressure; VE/VC02-slope, slope of increase of ventilation relative to carbon dioxide production; VO2peak, oxygen consumption at peak exercise.
and severity of sleep apnea included just 11 patients and checked only the \( \dot{V}O_2 \) at peak exercise. Anthropometric characteristics such as age and weight are also factors that could influence exercise capacity.\(^8\) The correlation between body mass index (BMI) and apnea-hypopnea index (AHI) in OSAS\(^9\) is well known, however, studies including OSAS patients and exercise capacity usually exclude severely obese patients due to the influence of BMI on the exercise capacity. One other valuable parameter that can be assessed during exercise is the ventilatory efficiency, demonstrated by the slope of increase of ventilation relative to carbon dioxide production (\( \dot{V}E/\dot{V}CO_2 \)-slope). The \( \dot{V}E/\dot{V}CO_2 \)-slope has been widely used to help in the interpretation of CPET in addition to \( \dot{V}O_2 \)\(_{\text{max}} \) and AT in cardiac impairments.\(^{10,11,12}\) However, the \( \dot{V}E/\dot{V}CO_2 \)-slope has never been addressed in OSAS patients.

In order to determine influences of anthropometric factors (age, BMI), severity of sleep apnea, and blood pressure (BP) on the exercise capacity and ventilatory efficiency of OSAS patients, we performed multiple linear regression analyses including independent variables of these parameters. We also compared the exercise capacity and ventilatory efficiency of OSAS patients with and without HT.

**METHODS**

**Patients**

Twenty-two men complaining of habitual snoring and/or daytime sleepiness hospitalized for a diagnosis of OSAS were included in the study. All of them were diagnosed from mild to severe OSAS on the basis of polysomnography (PSG). Exclusion criteria included: diabetes mellitus, heart failure, chronic obstructive lung disease, renal failure, anemia, myopathy, and other musculoskeletal disabilities as evaluated by clinical history, physical examination, electrocardiography (ECG), and spirometry. Patients were divided into two groups according to the presence of HT. HT was defined as systolic BP (SBP) > 140 mmHg and/or diastolic BP (DBP) > 90 mmHg. In the hypertensive group, we included patients currently taking antihypertensive medications and patients with HT in their medical records. Five patients with HT were on antihypertensive drugs, which included: calcium antagonists, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, and diuretics. Some patients were taking more than one drug at the same time. The CPET was performed as a routine clinical evaluation of the exercise ability of OSAS patients at Niigata University Medical and Dental Hospital. All participants were duly informed about the exercise protocol and the written consent was also obtained before the study.

**Pulmonary function test**

Spirometry was performed prior to entry into the study with the model Chestac-55V (Chest M.I. Inc., Tokyo), according to the American Thoracic Society standardization.\(^{13}\) The following function tests were performed: vital capacity (VC), and forced expiratory volume in 1s (FEV\(_1\)). In addition, the FEV\(_1\)/FVC (forced vital capacity) was determined. The maximum ventilatory ventilation (MVV) was indirectly estimated multiplying FEV\(_1\) by 40.\(^8\)

**Polysomnography**

Overnight sleep studies were performed with full PSG (Somnostar; SensorMedics, Yorba Linda, CA, USA), including the following measurements: electroencephalography (EEG), electromyography, electrooculography, ECG, airflow by oronasal thermistor, chest and abdominal wall movements, oxygen saturation (SpO\(_2\)) by pulse oximeter, snoring sounds by tracheal microphone, and body position. The findings were defined according to the recommendations advocated by the American Academy of Sleep Medicine (AASM) in 1999.\(^{14}\) Briefly, apnea was defined as the complete absence of oronasal airflow for at least 10s. Hypopnea was defined as a > 50 % decrease in oronasal airflow accompanied by a 3% fall in SpO\(_2\) from the baseline or an EEG arousal from sleep. Sleep-disordered breathing was assessed by apnea-hypopnea index (AHI), the cumulative percentage of sleep time with SpO\(_2\) below 90% (CT 90%) and the lowest SpO\(_2\) (LoSpO\(_2\)).

**Exercise testing**

Symptom-limited CPET was performed on a stationary cycle ergometer (Combi 232CXL, Tokyo). After a three min rest period, followed by three min of unloaded cycling (warm-up) on 55 revolutions/min, exercise intensity was increased incrementally by 10 to 20 W/min, depending on the patient’s age and condition, to allow each subject to reach a maximum within 8 – 12 min. All patients were encouraged to exercise to exhaustion. \( \dot{V}O_2 \), CO\(_2\) production (\( \dot{V}CO_2 \)), minute ventilation (\( \dot{V}E \)) and respiratory frequency (f) were continuously measured using a breath-by-breath gas analyzer (Minato AE280S, Osaka) with paramagnetic oxygen and photometric CO\(_2\) gas analyses. Gas exchange variables were calculated and summarized every 30s. The respiratory exchange ratio (RER) was calculated as the ratio of \( \dot{V}CO_2/\dot{V}O_2 \). The AT was determined using the V-slope method, as previously described.\(^{8,15}\) The \( \dot{V}O_2 \) at peak exercise (\( \dot{V}O_2 \)\(_{\text{peak}} \)) was
Table 1. Anthropometric characteristics, spirometry, and polysomnography data of the study subjects

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mean ± SD (n = 22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>51.1 ± 13.7</td>
</tr>
<tr>
<td>Height, cm</td>
<td>167.6 ± 6.1</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>83.2 ± 17.9</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>29.5 ± 5.5</td>
</tr>
<tr>
<td>VC, % predicted</td>
<td>111.9 ± 18.0</td>
</tr>
<tr>
<td>FEV₁/FVC, %</td>
<td>78.1 ± 7.1</td>
</tr>
<tr>
<td>FEV₁, % predicted</td>
<td>102.8 ± 18.7</td>
</tr>
<tr>
<td>MVV, L/min</td>
<td>126.5 ± 31.9</td>
</tr>
<tr>
<td>AHI, events/h</td>
<td>47.4 ± 30.4</td>
</tr>
<tr>
<td>CT90%, %</td>
<td>20.7 ± 27.2</td>
</tr>
<tr>
<td>LoSpO₂, %</td>
<td>79.9 ± 10.1</td>
</tr>
</tbody>
</table>

Values represent mean ± SD. MVV, maximum voluntary ventilation; AHI, apnea-hypopnea index; CT90%, cumulative percentage of sleep time with oxygen saturation below 90%; LoSpO₂, lowest oxygen saturation.

Table 2. Comparison of anthropometric characteristics, spirometry, and polysomnography data between no-hypertension (HT) and HT groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No-HT group (n = 8)</th>
<th>HT group (n = 14)</th>
<th>p-values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>44.1 ± 14.9</td>
<td>55.0 ± 11.7</td>
<td>0.109</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>29.5 ± 6.6</td>
<td>29.5 ± 5.0</td>
<td>0.633</td>
</tr>
<tr>
<td>VC, % predicted</td>
<td>112.9 ± 15.6</td>
<td>111.3 ± 19.8</td>
<td>0.973</td>
</tr>
<tr>
<td>FEV₁/FVC, %</td>
<td>81.1 ± 6.1</td>
<td>78.6 ± 8.0</td>
<td>0.088</td>
</tr>
<tr>
<td>FEV₁, % predicted</td>
<td>105.7 ± 14.4</td>
<td>104.5 ± 21.1</td>
<td>0.339</td>
</tr>
<tr>
<td>MVV, L/min</td>
<td>140.8 ± 36.6</td>
<td>118.4 ± 26.9</td>
<td>0.172</td>
</tr>
<tr>
<td>AHI, events/h</td>
<td>45.7 ± 28.1</td>
<td>48.3 ± 33.2</td>
<td>0.785</td>
</tr>
<tr>
<td>CT90%, %</td>
<td>23.8 ± 26.7</td>
<td>19.0 ± 28.3</td>
<td>0.375</td>
</tr>
<tr>
<td>LoSpO₂, %</td>
<td>77.1 ± 12.1</td>
<td>81.4 ± 8.9</td>
<td>0.306</td>
</tr>
</tbody>
</table>

Mann-Whitney U test between no-HT and HT groups. Values represent mean ± SD. MVV, maximum voluntary ventilation; CT90%, cumulative percentage of sleep time with oxygen saturation below 90%; LoSpO₂, lowest oxygen saturation.
Table 3. Comparisons of cardiopulmonary exercise testing (CPET) data between no-HT and HT groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No-HT group (n = 8)</th>
<th>HT group (n = 14)</th>
<th>p-values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rest</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RERrest,</td>
<td>0.89 ± 0.1</td>
<td>0.9 ± 0.1</td>
<td>0.785</td>
</tr>
<tr>
<td>HRrest, beats/min</td>
<td>79.0 ± 8.0</td>
<td>74.9 ± 10.7</td>
<td>0.125</td>
</tr>
<tr>
<td>SBPrest, mmHg</td>
<td>128.2 ± 8.2</td>
<td>142.9 ± 11.7</td>
<td>0.009</td>
</tr>
<tr>
<td>DBPrest, mmHg</td>
<td>81.8 ± 7.8</td>
<td>95.0 ± 9.3</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Peak exercise</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RERpeak</td>
<td>1.21 ± 0.1</td>
<td>1.15 ± 0.1</td>
<td>0.172</td>
</tr>
<tr>
<td>VE, L/min</td>
<td>66.9 ± 19.8</td>
<td>68.9 ± 13.4</td>
<td>0.733</td>
</tr>
<tr>
<td>f, cycles/min</td>
<td>30.7 ± 5.5</td>
<td>34.0 ± 5.4</td>
<td>0.133</td>
</tr>
<tr>
<td>BR, %</td>
<td>47.9 ± 9.2</td>
<td>61.3 ± 19.7</td>
<td>0.101</td>
</tr>
<tr>
<td>O₂ pulse, mL/beat/min</td>
<td>12.2 ± 2.6</td>
<td>12.9 ± 2.6</td>
<td>0.413</td>
</tr>
<tr>
<td>maximal load, W</td>
<td>143.9 ± 38.7</td>
<td>148.7 ± 30.8</td>
<td>&gt; 0.999</td>
</tr>
<tr>
<td>SpO₂, %</td>
<td>97.0 ± 2.5</td>
<td>96.2 ± 1.5</td>
<td>0.056</td>
</tr>
<tr>
<td>PETCO₂, mmHg</td>
<td>42.2 ± 3.0</td>
<td>40.0 ± 3.1</td>
<td>0.095</td>
</tr>
<tr>
<td>HRpeak, beats/min</td>
<td>148.6 ± 26.0</td>
<td>145.7 ± 16.6</td>
<td>0.838</td>
</tr>
<tr>
<td>SBPpeak, mmHg</td>
<td>212.8 ± 31.5</td>
<td>218.0 ± 25.9</td>
<td>0.785</td>
</tr>
<tr>
<td>SDBpeak, mmHg</td>
<td>106.4 ± 19.0</td>
<td>117.4 ± 17.1</td>
<td>0.322</td>
</tr>
<tr>
<td>VO₂peak, mL/min</td>
<td>1792.6 ± 394.0</td>
<td>1881.6 ± 419.5</td>
<td>0.838</td>
</tr>
<tr>
<td>VO₂peak, mL/kg/min</td>
<td>21.7 ± 4.2</td>
<td>23.1 ± 4.9</td>
<td>0.585</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AT, mL/min</td>
<td>1006.8 ± 267.2</td>
<td>1015.2 ± 267.2</td>
<td>0.891</td>
</tr>
<tr>
<td>AT, mL/kg/min</td>
<td>12.0 ±1.5</td>
<td>12.5 ± 1.6</td>
<td>0.517</td>
</tr>
<tr>
<td>VE/VO₂-slope</td>
<td>23.6 ± 2.0</td>
<td>27.0 ± 2.6</td>
<td>0.008</td>
</tr>
</tbody>
</table>

Mann-Whitney U test between no-HT and HT groups. Values represent mean ± SD. RER, respiratory exchange ratio; SPBrest, DBPrest, SBPpeak, DBPpeak, systolic and diastolic blood pressure at rest and at peak exercise, respectively; VE, minute ventilation, f, respiratory frequency; BR, breathing reserve; O₂ pulse, oxygen pulse; PETCO₂, end-tidal PCO₂, VO₂peak, oxygen consumption at peak exercise; AT, anaerobic threshold; VE/VO₂-slope, slope of increase of ventilation relative to carbon dioxide production.

calculated by averaging values obtained during the final 30s of exercise. The ECG and heart rate (HR) were monitored throughout the test. The oxygen pulse (O₂ pulse) was obtained by dividing the VO₂ peak in mL/min by maximum HR in beats/min. The breathing reserve (BR), defined as the percentage of MVV achieved at peak exercise, was calculated as BR = (VEpeak/MVV) x100. Cuff BP was also measured twice before the test by the examining physician using a mercury column sphygmomanometer, and the average values were used to derive the SBP and DBP at rest (SBPrest and DBPrest, respectively). BP was measured throughout the test every minute. The VE/VO₂-slope was calculated by a linear regression analysis excluding data above the ventilatory compensation point.10,16 There were no complications from the exercise tests, and all patients stopped
exercising due to leg fatigue and/or dyspnea. These data of the exercise test were obtained in accordance with the guidelines of the American Thoracic Society.23

**Statistical analysis**

All descriptive data are expressed as the mean ± SD. The multiple linear regression analysis — including all independent variables — was performed to determine the most influential predictor(s) of exercise ability. The Mann-Whitney U test was utilized to assess differences between patients with and without HT. A value of p < 0.05 was considered to be statistically significant.

**RESULTS**

The clinical characteristics of the patients are shown in Table 1. In CPET, all subjects were able to achieve a maximal respiratory exchange ratio (\( \dot{V}CO_2/\dot{V}O_2 \)) ≥ 1.04, indicating achievement of at least near maximal exercise.

The multiple linear regression analysis was performed to evaluate the effect of age, BMI, SBPrest, DBPrest, AHI, CT 90%, and LoSpO2 on the dependent variables of the \( \dot{V}O_{2\text{peak}} \) and \( \dot{V}E/\dot{V}CO_2 \)-slope. No factors emerged as predictive values of \( \dot{V}O_{2\text{peak}} \). The factors that emerged as the predictive variables of the \( \dot{V}E/\dot{V}CO_2 \)-slope in the multiple linear regression analysis were BMI as a significant negative predictor (p = 0.019), and AHI as a significant positive predictor (p = 0.047). The equation that describes this relationship is

\[
\dot{V}E/\dot{V}CO_2 \text{-slope} = -0.53 \times \text{BMI} + 0.09 \times \text{AHI} + 16.2 \quad (r^2 = 0.28).
\]

The remaining factors were not included as predictive factors.

We then divided 22 patients with OSAS into two groups: OSAS without HT (no-HT group), and OSAS with HT (HT group). Comparison between the no-HT and HT groups revealed no differences between them regarding the anthropometric characteristics and severity of sleep apnea (Table 2). Comparisons of CPET results between no-HT and HT groups indicated that, although no differences were found in either the \( \dot{V}O_{2\text{peak}} \) or AT between them, whether or not correcting the values for body weight, the HT group presented higher \( \dot{V}E/\dot{V}CO_2 \)-slope (p = 0.008) when compared with the no-HT group (Table 3). Even after excluding five patients from the HT group taking antihypertensive medications the \( \dot{VE}/\dot{V}CO_2 \)-slope was significantly different between the two groups (p = 0.012).

**DISCUSSION**

In the present study we examined the factors that could influence the exercise capacity and ventilatory efficiency of OSAS patients, giving special attention to the presence of HT. The major findings of this study were that BMI and AHI could be included as predictive variables of the \( \dot{VE}/\dot{V}CO_2 \)-slope, whereas no factors emerged as predictors of \( \dot{VO}_{2\text{peak}} \). Comparisons of CPET results between HT and no-HT patients showed that the \( \dot{V}CO_2 \)-slope was higher in the HT group. These results suggest that AHI can influence the ventilatory efficiency in addition to BMI and HT.

Previous studies addressing exercise capacity in OSAS patients focused on AT and \( \dot{VO}_{2\text{max}} \). Vanuxem et al. showed about 20% lower maximal oxygen consumption in OSAS patients than in the control subjects.3,17 Lin et al. also reported a significant decrease in \( \dot{VO}_{2\text{peak}} \) and AT in OSAS patients compared with normal controls.4 However, no study of OSAS patients has ever included the \( \dot{VE}/\dot{V}CO_2 \)-slope. The \( \dot{VE}/\dot{V}CO_2 \)-slope is a CPET-derived variable that is generally independent from subject effort, easily calculated, and has potential to supply additional information to the interpretation of exercise testing. We therefore looked at the ventilatory efficiency demonstrated by the \( \dot{VE}/\dot{V}CO_2 \)-slope in patients with OSAS. Central and peripheral chemoreceptors exert a powerful influence on breathing; the peripheral chemoreceptors respond primarily to hypoxic stimulation whereas the central chemoreceptors respond primarily to hypercapnia. The \( \dot{VE}/\dot{V}CO_2 \)-slope is used as an index of the ventilatory response to exercise.10 The ventilatory response to exercise is related to both hypoxic and hypercapnic chemosensitivity in healthy subjects18,19 and in chronic heart failure patients.20 In other words, the \( \dot{VE}/\dot{V}CO_2 \)-slope may reflect the way the patient’s ventilation responds to changes in arterial blood gases. The higher the stimulus to ventilation due to enhanced chemosensitivity, the higher the values of the \( \dot{VE}/\dot{V}CO_2 \)-slope.20

In the multiple linear regression analysis, BMI appeared as a negative predictor of the \( \dot{VE}/\dot{V}CO_2 \)-slope. It has been shown that obesity could in certain cases lead to hypoventilation, this being especially true in cases of obesity-hypoventilation syndrome, i.e. obesity with hypercapnia, due to the depression of ventilatory control.21 In addition, Lopata and Onal22 have shown that obese OSAS patients with or without hypercapnia are unable to increase the respiratory muscle drive and output as expected, which could explain the possible negative influence of BMI on the \( \dot{VE}/\dot{V}CO_2 \)-slope. We also found that AHI appeared as a positive predictor of the \( \dot{VE}/\dot{V}CO_2 \)-slope. Studies addressing chemosensitivity in OSAS patients have primarily examined the ventilatory response to hypoxia and have reported conflicting results. Some of them showed an increased23,24 but others a decreased ventilatory response to hypoxia.25,26 One of these studies found a positive correlation between AHI and peripheral chemosensitivity in OSAS patients;26 therefore, chemoreceptors might be related to an altered...
ventilatory response in these patients. In addition to
the pharyngeal anatomy and muscle regulation during
sleep, ventilatory control is supposed to be one of the
factors contributing to obstructive sleep apnea. The
quantity and pattern of ventilation in normal subjects are
tightly regulated to both maintain oxygen and carbon
dioxide levels within narrow limits and to minimize
the respiratory work. This is a product of multiple
feedback loops, including the chemoreceptors (O2 and
CO2), intrapulmonary receptors, and respiratory muscle
afferents and others. Especially, a change in PCO2 will
initiate a series of events to quickly correct the change
and return PCO2 to the desired level. To evaluate this
response, a “loop gain” index is used. A higher loop gain
in patients with sleep apnea than in control subjects was
demonstrated, and the higher the AHI, the higher the
loop gain. This loop gain is the product of the plant
gain and the controller gain. The plant gain is the ability
to eliminate CO2, and the controller gain is the response
of ventilation to the change in arterial CO2 tension. The
VE/VO2-slope measured in our study is similar to
the controller gain because it evaluates the response of
the ventilation to the change in CO2. It is possible that
a higher VE/VO2-slope may increase the respiratory
output, enhancing the negative pressure which could
collapse the upper airway causing even more severe sleep
apnea.

As BMI is positively correlated to AHI in this being
also true in our sample group (data not shown), this
opposite influence of both parameters on VE/VO2-slope
seems controversial. It has been reported, however, that
the ventilatory response in OSAS varies according to
the degree of underlying HT, and the presence of HT
was not exclusive to obese patients in our study group.
The VE/VO2-slope was higher in the HT group when
compared with the no-HT group (Table 3), despite the
absence of any differences in age, respiratory function,
or BMI between the groups (Table 2). The VE/VO2-slope
was not abnormally high in the HT group, but it was statistically higher than the no-HT group, a
difference which could possibly arise from the higher
peripheral chemosensitivity demonstrated in hypertensive
subjects.

Our study has several limitations. First of all, HT in
hypertensive patients was mild or moderate; possible
differences in exercise capacity could be found in patients
with severe HT. Second, we did not directly measure the
chemosensitivity to hypoxia or hypercapnia. Decreased
pulmonary perfusion and cardiac output could alter the
VE/VO2-slope; however, we excluded subjects with pulmonary and/or cardiac dysfunction and therefore
believe that the results of our study were most probably
influenced by chemosensitivity.

Our results suggest that the severity of sleep apnea
(AHI), obesity, and the presence of HT can influence
the ventilatory efficiency (VE/VO2-slope) of OSAS
patients.

REFERENCES

1) Bardwell WA, Moore P, Ancoli-Israel S, Dimsdale
JE: Fatigue in obstructive sleep apnea: driven by
depressive symptoms instead of apnea severity? Am

2) ATS/ACCP Statement on cardiopulmonary exercise
testing. Am J Resp Crit Care Med 167: 211-277,
2003.

3) Vanuxem D, Badier M, Guillot C, Delpierre S,
Jahjah F, Vanuxem P: Impairment of muscle energy
metabolism in patients with sleep apnoea syndrome.

4) Lin C-C, Hsieh W-Y, Chou C-S, Liaw S-F:
Cardiopulmonary exercise testing in obstructive
sleep apnea syndrome. Respir Physiol Neurobiol

5) Bonanni E, Pasquali L, Manca ML, Maestri M,
Prontera C, Fabbrini M, Berrettini S, Zucchelli
G, Siciliano G, Murri L: Lactate production and
catecholamine profile during aerobic exercise in
normotensive OSAS patients. Sleep Med 5: 137-145,
2004.

6) Taguchi O, Hida W, Okabe S, Ebihara S, Ogawa
H, Kikuchi Y, Shirato K: Improvement of exercise
performance with short-term nasal continuous
positive airway pressure in patients with obstructive

7) Lin C-C, Lin C-L, Wu K-M, Chou C-S: Effect
of treatment by nasal CPAP on cardiopulmonary
exercise test in obstructive sleep apnea syndrome.

8) Wasserman K, Hansen JE, Sue DY, Casaburi
R, Whipp BJ: Principles of exercise testing and
interpretation. 3rd ed. Baltimore: Lippincott
Williams & Wilkins, 1999.

9) Barvax VA, Aubert G, Rodenstein DO: Weight loss

10) Buller NP, Poole-Wilson PA: Mechanism of the
increased ventilatory response to exercise in patients
with chronic heart failure. Br Heart J 63: 281-283,
1990.

11) Theodore J, Robin ED, Morris AJ, Burke CM,
Jamieson SW, Van Kessel A, Stinson EB, Shumway
NE: Augmented ventilatory response to exercise in

12) Sullivan MJ, Higginbotham MB, Cobb FR:
Increased exercise ventilation in patients with chronic
heart failure: intact ventilatory control despite
hemodynamic and pulmonary abnormalities.


